• Dibutyryl-cAMP, Sodium Salt: Applied Workflows in cAMP Signa

  2026-06-06

  Dibutyryl-cAMP, sodium salt streamlines cAMP pathway activation for cell-based assays, enabling reproducible insights into neurodevelopment, inflammation, and cell differentiation. Its stability, cell-permeability, and compatibility with advanced differentiation platforms make it an essential tool for dissecting cAMP-mediated processes in both routine and high-throughput research.

• Chenodeoxycholic Acid: Enabling Precision in Cholesterol and

  2026-06-05

  Explore how Chenodeoxycholic Acid (CDCA) advances cholesterol metabolism research and nuclear receptor signaling studies. This article offers a deep scientific analysis and practical protocols, setting it apart from existing reviews.

• Dibutyryl-cAMP, Sodium Salt: Driving Precision in cAMP Resea

  2026-06-05

  Dibutyryl-cAMP, sodium salt (DBcAMP sodium salt) empowers researchers to dissect cAMP-dependent signaling with unparalleled control and consistency. From optimizing neuronal reprogramming to robust inflammation and proliferation assays, this cell-permeable analog—backed by APExBIO—elevates both data quality and workflow reliability.

• Structural Insights into FADD–Procaspase-8–cFLIP Assembly in

  2026-06-04

  This study delivers the first atomic-level structures of human FADD–procaspase-8–cFLIP complexes, illuminating the mechanisms by which these multiprotein assemblies regulate cell fate decisions in death receptor signaling. The findings clarify how DED-driven assembly controls apoptosis and necroptosis, offering valuable implications for cancer research and the rational design of apoptosis-modulating interventions.

• Tolazoline: α2-Adrenergic Receptor Antagonist in Translation

  2026-06-04

  Tolazoline stands out as a dual-action research tool for dissecting α2-adrenergic receptor signaling and insulin secretion modulation in both islet biology and airway smooth muscle studies. This article details evidence-based workflows, troubleshooting tips, and advanced applications for APExBIO's Tolazoline, empowering researchers to generate reproducible, high-impact data.

• Gefitinib (ZD1839) in Patient-Derived Cancer Assembloids

  2026-06-03

  Gefitinib (ZD1839) enables high-fidelity EGFR pathway inhibition and apoptosis induction in advanced cancer models, including assembloids that capture tumor–stroma complexity. This guide translates the latest evidence into actionable workflows, troubleshooting insights, and practical advantages for translational drug discovery.

• Carfilzomib (PR-171): Proteasome Inhibition for Multi-Modal

  2026-06-03

  This thought-leadership article unpacks the mechanistic innovations and translational opportunities unlocked by Carfilzomib (PR-171) in cancer research. By integrating recent mechanistic evidence with hands-on protocol guidance, it provides a strategic roadmap for translational researchers seeking to harness proteasome inhibition for robust, multi-modal cell death induction—including radiosensitization and ER stress modulation. The discussion uniquely contextualizes Carfilzomib’s role in emerging combination therapies for esophageal squamous cell carcinoma and establishes new best practices for translational study design.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf

  2026-06-02

  EPI-001 enables direct interrogation of androgen receptor signaling—uniquely targeting both full-length AR and resistant ARv7 variants. This guide translates recent breakthroughs into actionable protocols, troubleshooting advice, and advanced applications for prostate cancer and TNBC research.

• ALT Cancer Cells: ATR Inhibition Sensitivity Reexamined

  2026-06-02

  This study rigorously tested whether cancer cells using alternative lengthening of telomeres (ALT) show general hypersensitivity to ATR inhibition, as previously proposed. By comparing multiple cell lines and using isogenic controls, the authors found no universal ALT-specific vulnerability, emphasizing the importance of genetic background in interpreting inhibitor studies.

• O-GlcNAcylation Regulates Ferroptosis and Syncytialization i

  2026-06-01

  This study uncovers how O-GlcNAc modification of HUWE1 orchestrates the ubiquitination and degradation of TfR1, thus regulating ferroptosis and syncytialization in preeclamptic placentas. The mechanistic insights into the O-GlcNAc–HUWE1–TfR1 axis reveal potential targets for therapeutic intervention in preeclampsia and deepen the understanding of placental oxidative stress pathways.

• Sodium Nitroprusside: Mechanistic Insight and Strategic Use

  2026-06-01

  This thought-leadership article dissects how Sodium Nitroprusside, a potent nitric oxide donor, empowers translational vascular research by enabling precise interrogation of vasodilation, platelet inhibition, and sex-specific mechanisms in hypertension. We blend mechanistic explanation with actionable protocol advice, referencing the latest sex-difference hypertension models and linking to both APExBIO product intelligence and laboratory best practices. The piece uniquely bridges mechanistic insight, translational relevance, and competitive product positioning, offering new perspectives beyond standard product pages.

• Indometacin Sodium Suppresses PSC Activation via COX-2 Downr

  2026-05-31

  This study demonstrates that indometacin sodium, a non-selective cyclooxygenase inhibitor, effectively suppresses both the proliferation and activation of human pancreatic stellate cells (PSCs) through COX-2 downregulation. These findings highlight a potential therapeutic strategy targeting stromal remodeling in pancreatic ductal adenocarcinoma and inform anti-inflammatory research involving tumor–stromal interactions.

• TRIM66 Epigenetic Control of Monogenic Olfactory Receptor Ex

  2026-05-30

  The reference study uncovers TRIM66 as a pivotal epigenetic repressor governing the singular expression of olfactory receptor genes in sensory neurons. This finding clarifies a long-standing mystery in sensory biology and provides new mechanistic insight into how neural diversity and precision arise at the molecular level.

• (S)-Mephenytoin: Applied Protocols for CYP2C19 Substrate Ass

  2026-05-29

  (S)-Mephenytoin, as a gold-standard CYP2C19 substrate, enables high-fidelity pharmacokinetic and oxidative drug metabolism studies in advanced in vitro systems. This guide distills experimental workflows, protocol optimizations, and troubleshooting strategies powered by APExBIO’s rigorously validated reagent, contextualized by the latest breakthrough in stem cell-derived intestinal organoid models.

• Causal Roles of CLEC5A and ISG20 in Atherosclerosis Progress

  2026-05-29

  Zhang et al. (2025) integrate Mendelian randomization and eQTL analyses to demonstrate that CLEC5A and ISG20 are causally implicated in atherosclerosis risk. Their study provides molecular evidence for ISG20’s role in macrophage-driven lipid accumulation and inflammation within atherosclerotic lesions, offering new insight into potential therapeutic targets.

15051 records 3/1004 page Previous Next 12345 下5页 Last page